The right drugs at the right time for the right patient: The MD Anderson precision oncology decision support platform

Drug Discovery Today

Volumn 20, Issue 12, 2015, Pages 1433-1438

  Johnson, Amber ^a   Zeng, Jia ^a   Bailey, Ann M ^a   Holla, Vijaykumar ^a   Litzenburger, Beate ^a   Lara Guerra, Humberto ^a   Mills, Gordon B ^a   Mendelsohn, John ^a   Shaw, Kenna R ^a   Meric Bernstam, Funda ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; ANTINEOPLASTIC AGENT;

CLINICAL DECISION MAKING; DECISION SUPPORT SYSTEM; EXPERIMENTAL THERAPY; FUNCTIONAL GENOMICS; GENOTYPE; HUMAN; OFF LABEL DRUG USE; PATIENT SELECTION; PRECISION ONCOLOGY DECISION SUPPORT; REVIEW; SOMATIC MUTATION; NEOPLASMS; ONCOLOGY; PERSONALIZED MEDICINE; PROCEDURES; RESEARCH;

ANTINEOPLASTIC AGENTS; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; PRECISION MEDICINE; RESEARCH;

EID: 84949534750     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2015.05.013     Document Type: Short Survey

References (32)

1. C. Le Tourneau, and et al. Randomised proof-of-concept Phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial Br. J. Cancer 111 2014 17 24
2. A.C. Wolff, and et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update J. Clin. Oncol. 31 2013 997 4013
3. I. Smith, and et al. 2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial Lancet 369 2007 29 36
4. D.J. Slamon, and et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N. Engl. J. Med. 344 2001 783 792
5. B.M. Welch, and K. Kawamoto The need for clinical decision support integrated with the electronic health record for the clinical application of whole genome sequencing information J. Pers. Med. 3 2013 306 325
6. N. Servant, and et al. Bioinformatics for precision medicine in oncology: principles and application to the SHIVA clinical trial Front. Genet. 5 2014 152
7. A. Sboner, and et al. The real cost of sequencing: higher than you think! Genome Biol. 12 2011 125
8. B. Tran, and et al. Cancer genomics: technology, discovery, and translation J. Clin. Oncol. 30 2012 647 660
9. F. Meric-Bernstam, and et al. A decision support framework for genomically-informed investigational cancer therapy J. Natl. Cancer Inst. 107 2015 10.1093/jnci/djv098
10. E.M. Van Allen, and et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine Nat. Med. 20 2014 682 688
11. H. Greulich, and P.M. Pollock Targeting mutant fibroblast growth factor receptors in cancer Trends Mol. Med. 17 2011 283 292
12. N. Turner, and R. Grose Fibroblast growth factor signalling: from development to cancer Nat. Rev. Cancer 10 2010 116 129
13. K.R. Kampen, and et al. Insights in dynamic kinome reprogramming as a consequence of MEK inhibition in MLL-rearranged AML Leukemia 28 2014 589 599
14. Y.P. Chen, and et al. CDKN1 A-mediated responsiveness of MLL-AF4-positive acute lymphoblastic leukemia to Aurora kinase-A inhibitors Int. J. Cancer 135 2014 751 762
15. S.R. Daigle, and et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia Blood 122 2013 1017 1025
16. R. Dienstmann, and et al. Standardized decision support in next generation sequencing reports of somatic cancer variants Mol. Oncol. 8 2014 859 873
17. Y. Mao, and et al. CanDrA: cancer-specific driver missense mutation annotation with optimized features PLOS ONE 8 2013 e77945
18. F. Di Nicolantonio, and et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus J. Clin. Invest. 120 2010 2858 2866
19. A.J. Templeton, and et al. Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08) Eur. Urol. 64 2013 150 158
20. A.M. Bailey, and et al. Implementation of biomarker-driven cancer therapy: existing tools and remaining gaps Discov. Med. 17 2014 101 114
21. N. Wagle, and et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing Cancer Discov. 2 2012 82 93
22. P.G. Febbo, and et al. NCCN Task Force report: evaluating the clinical utility of tumor markers in oncology J. Natl. Compr. Cancer Netw. 9 2011 S1 S32
23. L.E. MacConaill, and et al. Prospective enterprise-level molecular genotyping of a cohort of cancer patients J. Mol. Diagn. 16 2014 660 672
24. V. Heinemann, and et al. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR Cancer Treat. Rev. 35 2009 262 271
25. H. Linardou, and et al. All about KRAS for clinical oncology practice: gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer Cancer Treat. Rev. 37 2011 221 233
26. J. Mazieres, and et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives J. Clin. Oncol. 31 2013 1997 2003
27. R. Bose, and et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer Cancer Discov. 3 2013 224 237
28. F. Vandin, and et al. De novo discovery of mutated driver pathways in cancer Genome Res. 22 2012 375 385
29. L. Wang, and D.A. Wheeler Genomic sequencing for cancer diagnosis and therapy Annu. Rev. Med. 65 2014 33 48
30. K. Chen, and et al. Clinical actionability enhanced through deep targeted sequencing of solid tumors Clin. Chem. 61 2015 544 553
31. P.H. Carney Information technology and precision medicine Semin. Oncol. Nurs. 30 2014 124 129
32. V. Huser, and et al. Developing genomic knowledge bases and databases to support clinical management: current perspectives Pharmgenomics Pers. Med. 7 2014 275 283